Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teaching | 1 | 2018 | 65 | 0.560 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 803 | 0.540 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 230 | 0.520 |
Why?
|
| Neoplasms | 2 | 2018 | 791 | 0.500 |
Why?
|
| Internship and Residency | 1 | 2018 | 330 | 0.440 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 627 | 0.380 |
Why?
|
| Taxoids | 4 | 2020 | 60 | 0.310 |
Why?
|
| Anthracyclines | 4 | 2017 | 62 | 0.290 |
Why?
|
| Thalidomide | 1 | 2007 | 34 | 0.260 |
Why?
|
| Scalp | 2 | 2017 | 38 | 0.250 |
Why?
|
| Alopecia | 2 | 2017 | 31 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2017 | 489 | 0.230 |
Why?
|
| Quality of Life | 3 | 2019 | 1032 | 0.200 |
Why?
|
| Esophageal Neoplasms | 3 | 2006 | 42 | 0.170 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.160 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.160 |
Why?
|
| Median Nerve | 1 | 2020 | 53 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 54 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 4 | 2017 | 70 | 0.150 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 48 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 96 | 0.140 |
Why?
|
| Middle Aged | 14 | 2020 | 12703 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2020 | 417 | 0.130 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 16 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 193 | 0.130 |
Why?
|
| Humans | 18 | 2020 | 34474 | 0.120 |
Why?
|
| Aged | 13 | 2020 | 10998 | 0.120 |
Why?
|
| Female | 16 | 2020 | 21490 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 349 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2006 | 58 | 0.120 |
Why?
|
| Radiopharmaceuticals | 2 | 2006 | 103 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 140 | 0.110 |
Why?
|
| Adult | 12 | 2017 | 10015 | 0.110 |
Why?
|
| Adenocarcinoma | 4 | 2006 | 317 | 0.110 |
Why?
|
| Aged, 80 and over | 8 | 2013 | 4150 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 222 | 0.110 |
Why?
|
| Paclitaxel | 2 | 2020 | 73 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 755 | 0.100 |
Why?
|
| Leukemia | 1 | 2013 | 43 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 40 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 75 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 229 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2005 | 133 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 214 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2020 | 2461 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 399 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 139 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2013 | 3618 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1176 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2020 | 583 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 37 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 212 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2014 | 176 | 0.060 |
Why?
|
| Camptothecin | 2 | 2005 | 52 | 0.060 |
Why?
|
| African Americans | 1 | 2013 | 1435 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2005 | 66 | 0.060 |
Why?
|
| Male | 9 | 2013 | 20697 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1209 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 925 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 589 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2002 | 86 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 32 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 47 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 49 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 40 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 50 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 71 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 92 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 350 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 934 | 0.030 |
Why?
|
| Social Support | 1 | 2019 | 195 | 0.030 |
Why?
|
| Medical Illustration | 1 | 2017 | 6 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 13 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 163 | 0.030 |
Why?
|
| Photography | 1 | 2017 | 45 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 78 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 325 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 110 | 0.030 |
Why?
|
| Young Adult | 2 | 2013 | 2825 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1607 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2014 | 3812 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 168 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 117 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2014 | 70 | 0.030 |
Why?
|
| Ergocalciferols | 1 | 2013 | 4 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 2013 | 13 | 0.020 |
Why?
|
| Troponin I | 1 | 2013 | 25 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 89 | 0.020 |
Why?
|
| Mastectomy | 1 | 2013 | 64 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 323 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 231 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 287 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1261 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2013 | 440 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 2352 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2366 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 25 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2007 | 30 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 924 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1386 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 98 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 170 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2006 | 18 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 14 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 29 | 0.010 |
Why?
|
| Vomiting | 1 | 2005 | 23 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 33 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 55 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 59 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 88 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 51 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 90 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 4136 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 176 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 3799 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 306 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 485 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 703 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 819 | 0.010 |
Why?
|
| Ethnic Groups | 1 | 2006 | 483 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 633 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 14 | 0.010 |
Why?
|
| Leucovorin | 1 | 2002 | 24 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 31 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 14 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 69 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 71 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 120 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 1910 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 164 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 452 | 0.010 |
Why?
|